Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-037995
Filing Date
2025-03-12
Accepted
2025-03-12 16:31:45
Documents
53
Period of Report
2025-01-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-20250131.htm   iXBRL 10-Q 1632068
2 EX-10.1 kalv-ex10_1.htm EX-10.1 622787
3 EX-10.2 kalv-ex10_2.htm EX-10.2 321454
4 EX-31.1 kalv-ex31_1.htm EX-31.1 18641
5 EX-31.2 kalv-ex31_2.htm EX-31.2 16664
6 EX-32.1 kalv-ex32_1.htm EX-32.1 11783
  Complete submission text file 0000950170-25-037995.txt   6701552

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kalv-20250131.xsd EX-101.SCH 713376
56 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20250131_htm.xml XML 841284
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 25732179
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)